The global race for a COVID-19 vaccine is heating up—and there’s keen discussion on claims and disclosures. Even as clinical trials are on, there’s a hectic parallel effort on the manufacturing and access front. After all, as the World Health Organization’s chief scientist Soumya Swaminathan put it recently, this is the first time that the world will need vaccines in billions of doses.
An actual licensed vaccine is still far off—at least mid-2021 for a limited dose to arrive in countries, according to WHO. So what does the current scenario look like? As of mid-September, there were 36 vaccine candidates in various stages of clinical trials (this includes Bharat Biotech’s indigenous vaccine called Covaxin) and 146 others in pre-clinical evaluation. Here’s a look at the candidates currently in Phase III trials.
ALSO READ: The Report In Blood